News Headlines Article

Glaxo Memo on Avandia Is Questioned
New York Times

Federal drug regulators ordered GlaxoSmithKline to send a letter to crucial doctors describing a hearing in July where an expert advisory panel discussed the risks of Avandia, the company’s controversial diabetes medicine. But a federal official and some members of the panel now say the company’s letter is misleading and could endanger patients. The dispute is occurring just weeks before the Food and Drug Administration is expected to announce whether Avandia’s label must include new warnings, whether sales of the drug will be restricted or whether Avandia must be withdrawn from the market.